全文获取类型
收费全文 | 20164篇 |
免费 | 1648篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 233篇 |
儿科学 | 565篇 |
妇产科学 | 515篇 |
基础医学 | 3033篇 |
口腔科学 | 512篇 |
临床医学 | 2094篇 |
内科学 | 3841篇 |
皮肤病学 | 274篇 |
神经病学 | 1800篇 |
特种医学 | 511篇 |
外国民族医学 | 2篇 |
外科学 | 2810篇 |
综合类 | 373篇 |
一般理论 | 20篇 |
预防医学 | 1891篇 |
眼科学 | 470篇 |
药学 | 1502篇 |
中国医学 | 37篇 |
肿瘤学 | 1383篇 |
出版年
2023年 | 146篇 |
2022年 | 282篇 |
2021年 | 592篇 |
2020年 | 325篇 |
2019年 | 449篇 |
2018年 | 533篇 |
2017年 | 361篇 |
2016年 | 387篇 |
2015年 | 423篇 |
2014年 | 549篇 |
2013年 | 881篇 |
2012年 | 1203篇 |
2011年 | 1181篇 |
2010年 | 679篇 |
2009年 | 572篇 |
2008年 | 1008篇 |
2007年 | 1057篇 |
2006年 | 1008篇 |
2005年 | 944篇 |
2004年 | 879篇 |
2003年 | 807篇 |
2002年 | 820篇 |
2001年 | 478篇 |
2000年 | 398篇 |
1999年 | 396篇 |
1998年 | 174篇 |
1997年 | 174篇 |
1996年 | 184篇 |
1995年 | 147篇 |
1994年 | 129篇 |
1993年 | 120篇 |
1992年 | 286篇 |
1991年 | 288篇 |
1990年 | 267篇 |
1989年 | 251篇 |
1988年 | 242篇 |
1987年 | 246篇 |
1986年 | 224篇 |
1985年 | 198篇 |
1984年 | 168篇 |
1983年 | 164篇 |
1982年 | 135篇 |
1981年 | 134篇 |
1980年 | 125篇 |
1979年 | 141篇 |
1978年 | 138篇 |
1976年 | 115篇 |
1974年 | 130篇 |
1973年 | 120篇 |
1972年 | 122篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献
12.
13.
We live in a technology-saturated world, evidenced by widespread, global use of the Internet and other forms of technology. Technology offers nearly limitless connectivity, information-sharing, and communication. Unfortunately, with these opportunities come risks, especially for children, and pediatric healthcare providers have a responsibility to be aware and informed of these risks and how to respond. This article provides a breakdown of the broad phenomenon of electronic aggression and offers practice implications for healthcare providers. 相似文献
14.
15.
A. A. Vo M. Toyoda A. Peng S. Bunnapradist M. Lukovsky S. C. Jordan 《American journal of transplantation》2006,6(10):2384-2390
Here we retrospectively examine the efficacy of two antibody induction regimens using Zenapax or Thymoglobulin in patients with positive complement-dependent cytotoxicity crossmatches (CDC-CMXs) desensitized with IVIG (intravenous immunoglobulin). Between January 1999 and March 2005, 97 patients with (+) CDC-CMXs received kidney transplants (43 deceased donors/54 living donors). All patients received at least 2 g/kg IVIG (maximum four doses) until an acceptable CMX was obtained. Patients were divided into two groups: 1. IVIG + Zenapax (n = 58), 2. IVIG + Thymoglobulin (n = 39). A total of 94% of patients in Group 1 and 84% in G2 have at least 2 years of follow up. Patient and graft survival was 96%/84% in Group 1 and 100%/90% in Group 2, p = NS. The number and severity of AR episodes were similar (36% Group 1 vs. 31% Group 2, p = NS) as was the incidence of C4d (+) antibody-mediated rejection (AMR) (Banff Grade II/III) (22% Group 1 vs. 21% Group 2). Mean serum creatinines (SCrs) at 24 months were similar (Group 1: 1.4 +/- 0.7 vs. G2: 1.5 +/- 0.7 mg/dL). Induction therapy with Zenapax or Thymoglobulin results in excellent patient, graft survival and graft function at 2 years. There was no increased risk of viral infections or malignancies with either agent. Neither agent was effective in reducing the incidence of AMR. 相似文献
16.
Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. 总被引:2,自引:0,他引:2
P F Schellhammer G H Jordan E L Robey J T Spaulding 《The Urologic clinics of North America》1992,19(1):131-142
Premalignant lesions of the penis include cutaneous horn, balanitis xerotica obliterans, and leukoplakia. The true incidence of progression of each of these to squamous-cell carcinoma is unknown. Bowenoid papulosis, erythroplasia of Queyrat, and Bowen's disease are histologically identical to in situ carcinoma. Although the first is consistently benign, the latter two regularly evolve into invasive cancer. Malignant scrotal lesions include squamous-cell carcinoma, liposarcoma, leiomyosarcoma, basal-cell carcinoma, extramammary Paget's disease, erythroplasia of Queyrat, malignant melanoma, and metastases. Hemangioma can be confused with carcinoma. 相似文献
17.
Christopher G. Acker Richard Flick Ron Shapiro Velma P. Scantlebury Mark L. Jordan Carlos Vivas Arthur Greenberg John P. Johnson 《American journal of transplantation》2002,2(1):57-61
Delayed graft function (DGF) in cadaver kidney transplants is a common problem and is often due to acute tubular necrosis (ATN). DGF in transplants may have a deleterious effect on long-term graft survival. Since thyroid hormone has been shown to hasten recovery from ATN in experimental models, we designed a trial to determine if a defined course of triiodothyronine (T3) would improve the short- or long-term outcome of patients with DGF in cadaveric transplants. A prospective, randomized, placebo controlled, double blind trial of T3 was carried out in patients with DGF in cadaveric renal transplants. End-points were percentage requiring dialysis, percentage recovering function, time to recovery and length of hospital stay. Long-term outcomes were percentage grafts functioning at 1 year and mean serum creatinine at 1 year. Forty-four patients were randomized to receive either T3 or placebo. Three patients were dropped from each group when early biopsies disclosed that DGF was due to rejection. The groups were well matched by age, cold ischemia time of the graft, and percentage reactivity to a random panel of antigens. Baseline thyroid function studies, including T3, reverse T3 (rT3), and thyroid stimulating hormone (TSH) levels, were similar between the two groups and typical of 'euthyroid-sick syndrome'. T3 had no effect on percentage requiring dialysis, time to recovery, percentage recovering function, or length of stay. At 1 year follow-up, graft function was similar in both groups and significantly lower than that seen in patients with good initial function. Thyroid hormone, given early in the course of DGF in cadaver kidney recipients, had no effect on the course of DGF. Long-term graft function is impaired in patients who experience post-transplant DGF compared to those who have good initial function. 相似文献
18.
19.
Anil K Jain Ravindra S Chauhan Ish K Dhammi Aditya V Maheshwari Ruma Ray 《The spine journal》2007,7(2):249-253
BACKGROUND CONTEXT: Pseudoaneurysm of the aorta in association with vertebral tuberculosis is a rare phenomenon. With the resurgence of human immunodeficiency virus (HIV) and associated resistant tuberculosis, this life-threatening complication requires greater awareness. PURPOSE: Our purpose is to report the rare presentation and successful management of tubercular pseudoaneurysm of the aorta in association with vertebral tuberculosis, and to highlight the clinicoradiological features for early and prompt diagnosis of this potentially fatal, but treatable, disease. STUDY DESIGN: A single case report and overview of the disease comprises the design of this study. PATIENT SAMPLE: The patient, already surgically intervened, is a 27-year-old male with increasing abdominal and back pain, upper motor neuron signs, and constitutional signs and symptoms. OUTCOME MEASURES: At 33 months follow-up, there is complete resolution of the signs and symptoms, and the patient is back to his previous vocation. METHODS: The diagnosis was confirmed by magnetic resonance imaging and contrast computed tomography. Endoaneurysmorrhaphy of the pseudoaneurysm along with a complete course of antitubercular treatment was given to the patient, and he has presently been followed up for 33 months. RESULTS: The patient's signs and symptoms have been completely resolved without any recurrence. CONCLUSION: Despite the use of modern chemotherapy and imaging techniques, this disastrous complication still occurs and reinforces the need for early suspicion, diagnosis, surgical resection, and antitubercular therapy along with close postoperative follow-up to prevent recurrence. With the resurgence of HIV (and other immunocompromised states) associated and resistant tuberculosis, we should be more alert than ever to this life-threatening complication. 相似文献
20.